What is HC Wainwright’s Estimate for CRSP FY2026 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued on Tuesday, November 3rd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($4.49) for the year, up from their previous forecast of ($4.53). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.44) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2026 earnings at ($1.12) EPS, Q1 2027 earnings at ($1.26) EPS, Q2 2027 earnings at ($1.18) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.23) EPS and FY2027 earnings at ($4.95) EPS.

A number of other research analysts have also recently weighed in on CRSP. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Citigroup raised their target price on shares of CRISPR Therapeutics from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research note on Monday, August 31st. William Blair upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Wall Street Zen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $69.69.

CRISPR Therapeutics Stock Up 3.6%

Shares of CRSP opened at $51.78 on Thursday. The company has a market cap of $5.01 billion, a PE ratio of -10.92 and a beta of 1.92. The business has a fifty day moving average of $53.67 and a 200 day moving average of $52.84. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $63.45. The company has a quick ratio of 17.85, a current ratio of 16.21 and a debt-to-equity ratio of 0.36.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.09). The company had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 25.59%. CRISPR Therapeutics’s quarterly revenue was up 1311.1% on a year-over-year basis.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 47,837 shares of the stock in a transaction on Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the sale, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the sale, the director owned 16,637 shares of the company’s stock, valued at approximately $949,806.33. This trade represents a 45.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 93,558 shares of company stock worth $4,881,663 in the last 90 days. 5.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CRSP. Choreo LLC increased its stake in CRISPR Therapeutics by 3.4% in the 3rd quarter. Choreo LLC now owns 7,539 shares of the company’s stock worth $417,000 after buying an additional 247 shares during the period. Sterling Capital Management LLC boosted its position in CRISPR Therapeutics by 15.5% in the 3rd quarter. Sterling Capital Management LLC now owns 1,934 shares of the company’s stock valued at $107,000 after buying an additional 260 shares during the period. Interchange Capital Partners LLC grew its stake in CRISPR Therapeutics by 6.0% in the 3rd quarter. Interchange Capital Partners LLC now owns 4,766 shares of the company’s stock worth $264,000 after acquiring an additional 268 shares in the last quarter. Versant Capital Management Inc grew its stake in CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares in the last quarter. Finally, Sunbelt Securities Inc. increased its position in shares of CRISPR Therapeutics by 4.5% during the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company’s stock worth $373,000 after acquiring an additional 336 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Key Headlines Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target to $90 from $88 and reaffirmed a “buy” rating, signaling significant potential upside in the analyst’s view. Citigroup price target report
• Positive Sentiment: The company said it will present Phase 1/2 clinical data for zugo-cel, its investigational gene-edited CAR T therapy for relapsed or refractory large B-cell lymphoma, at the ASH meeting in December. The presentation could provide investors with a meaningful pipeline update. Zugo-cel clinical data announcement
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His experience in manufacturing, gene editing and commercial launches may support the company’s operations, though the appointment’s financial impact is not yet clear. Chief technical officer appointment
• Negative Sentiment: Third-quarter results fell short of expectations: the company reported a $1.15-per-share loss versus the $1.06 loss analysts expected, and revenue of $12.67 million versus a $14.75 million consensus estimate. Growing Casgevy use and sales offer a counterpoint, but the earnings shortfall may weigh on sentiment. Third-quarter results coverage
• Negative Sentiment: Brookline Capital Markets slightly lowered its projected earnings per share for 2028, 2029 and 2030, a modestly cautious revision to its long-term outlook.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.